Invitation to Roche’s Virtual Ophthalmology Investor Event
2025-10-03
 We are pleased to invite investors and analysts to participate in our virtual event on Tuesday, 21 October 2025, to highlight new results from Roche’s Ophthalmology pipeline including Phase III (SANDCAT/MEERKAT) vamikibart in UME data presented at the American Academy of Ophthalmology (AAO) from 18-20 October 2025, as well as Phase III (SatraGo-1/SatraGo-2) satralizumab in TED data presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS 2025) from 16-17 October 2025. 17:00 - 18:00 CEST / 16:00 - 17:00 BST 11:00 am - 12:00 pm EDT / 08:00 - 09:00 am PDT The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 16:00 CEST on the day of the event. > click here Access to virtual event (pre-registration required) Please pre-register for our webinar here*. Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com. A replay of the webcast will be available via > ir.roche.com *privacy notice Best regards, |
| Bruno Eschli Head of Investor Relations | Loren Kalm Head of Investor Relations, North America |
| Roche Investor Relations | |
| Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com | Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
| Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com | |
| | |
| Investor Relations North America | |
| Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com | |
Investors
Investor updates
stay updated
get the latest news and updates to your inbox.